Patents Court finds triple combination SPC for HIV-1 treatment Atripla invalid
Following his decision to refer questions to the Court of Justice of the European Union relating to the SPC for Gilead's Truvada product, Arnold J has decided, in the light of the relevant claim in the basic Patent, that the SPC for the triple combination product Atripla (marketed by Gilead and Bristol-Myers Squibb) is invalid.
Read more